Crystalline Polymorph Characterization for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in obtaining a crystal form of the compound A with excellent physicochemical stability, as crystalline polymorphisms and instability issues complicate pharmaceutical product development, affecting drug efficacy and side effects.
Innovation Solution
The formation of specific crystalline polymorphs, Form-I and Form-II, characterized by distinct diffraction peaks and thermal properties, along with a pharmaceutical composition containing these crystals, is achieved through thorough research and characterization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If various conditions are studied for each compound to obtain a crystal, then a crystal can be obtained, but the process is time-consuming and complex
Solution Approach 1:
The patent performs preliminary crystal screening actions by testing multiple solvents and conditions in advance to identify the most promising crystal forms before full-scale production. This preliminary characterization data is then used to guide subsequent crystal growth experiments, reducing the overall time required for crystal development.
Solution Approach 2:
The patent systematically varies crystallization parameters including solvent type, temperature, pH, and concentration to obtain different crystal forms. By methodically changing these parameters and characterizing the resulting crystals, the patent identifies optimal conditions for obtaining stable crystal forms of compound A more efficiently.
2Stability of the object's composition
If strict evaluations and studies regarding physicochemical stability are performed, then stability is ensured, but the development process becomes more complex
Solution Approach 1:
The patent performs preliminary stability assessments by evaluating multiple crystal forms under various storage conditions early in the development process. This includes assessing crystalline polymorphism, purity maintenance, and physical stability before selecting the final crystal form for further development, thereby simplifying subsequent evaluation steps.
Solution Approach 2:
The patent employs analytical techniques such as X-ray powder diffraction, differential scanning calorimetry, and spectroscopy to objectively characterize and compare the physicochemical stability of different crystal forms. These analytical methods replace subjective assessment with quantifiable data, streamlining the stability evaluation process.
3Reliability
If an inappropriate crystal form is selected, then drug efficacy may decrease or side effects may occur, but identifying the appropriate crystal form requires extensive screening
Solution Approach 1:
The patent conducts preliminary characterization of potential crystal forms to assess their suitability for pharmaceutical use before committing to extensive development of any single form. This includes evaluating stability, purity, and physical properties to identify the most promising crystal form early in the process.
Solution Approach 2:
The patent systematically varies crystallization parameters to generate and evaluate multiple crystal forms, then compares their properties to identify the optimal form for pharmaceutical use. This methodical approach ensures that the selected crystal form has the desired stability and efficacy characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified crystal forms provide enhanced physicochemical stability, ensuring consistent drug quality and efficacy, and can be used in treating various cancers and inflammatory diseases by maintaining therapeutic effects.
Implementation Method 1
showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ
Implementation Method 2
X-ray powder diffraction spectrum is obtained by using Cu Kα radiation
Implementation Method 3
having an endothermic peak at 203±3° C. in differential scanning calorimetry
Data Source
AI summary
A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å).